Renaissance Technologies LLC Has $2.02 Million Position in Certara, Inc. $CERT

Renaissance Technologies LLC raised its stake in Certara, Inc. (NASDAQ:CERT) by 1,097.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 354,500 shares of the company’s stock after buying an additional 324,900 shares during the period. Renaissance Technologies LLC owned about 0.23% of Certara worth $2,021,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Certara by 2,733.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after acquiring an additional 2,870 shares during the period. Osaic Holdings Inc. increased its position in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the period. Tower Research Capital LLC TRC increased its position in Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after purchasing an additional 4,930 shares during the period. Chicago Partners Investment Group LLC bought a new position in Certara during the 1st quarter worth approximately $78,000. Finally, Kera Capital Partners Inc. bought a new position in Certara during the 1st quarter worth approximately $80,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Performance

Shares of CERT opened at $8.13 on Wednesday. Certara, Inc. has a one year low of $4.45 and a one year high of $13.88. The company has a market cap of $1.24 billion, a PE ratio of -18.07 and a beta of 1.44. The stock has a 50-day moving average of $6.65 and a 200-day moving average of $6.51. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same period last year, the company posted $0.07 earnings per share. On average, equities research analysts predict that Certara, Inc. will post 0.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CERT has been the topic of a number of analyst reports. Stephens reduced their price objective on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. BMO Capital Markets lowered their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Tuesday, May 12th. Craig Hallum lowered their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings upgraded shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. Finally, Robert W. Baird cut their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Certara currently has a consensus rating of “Hold” and a consensus target price of $8.28.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.